Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The study is designed to evaluate the efficacy and safety of each dose of SHP465 (12.5 and 37.5 mg) given to participants daily in the morning compared to placebo in the treatment of adults aged 18 to 55 years diagnosed with ADHD.
Epistemonikos ID: 0a84f0376276c431fed311e55d27b3ce41a8738b
First added on: May 12, 2024